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Summary. Background: Our previous studies
demonstrated the expression of procollagen11A1 in
fibroblasts of pancreatic cancer desmoplasia and the lack
of expression in fibroblasts of pancreatitis by means of
the polyclonal antibody (anti-proCOL11A1 pAb) we
generated. In a similar way, we decided to compare the
expression of procollagen11A1 in fibroblasts of
infiltrating ductal carcinoma of the breast and fibroblasts
of benign sclerosing lesions of the breast, in order to
validate the anti-proCOL11A1 pAb in this setting and to
study how proCOL11A1 expression relates to other
prognostic and predictive factors, as well as to survival.
Methods: 45 core biopsies of sclerosing adenosis and 50
core biopsies of infiltrating ductal carcinoma of the
breast were stained with anti-proCOL11A1 pAb, a
polyclonal antibody highly specific to the less
homologous fraction of proCOL11A1 (in comparison
with proCOL5A1 and proCOL11A2). In addition, the
expression of the proCOL11A1 gene was measured by
RT-qPCR. On the other hand, the expression of
proCOL11A1 was compared to the expression of
estrogenic receptors, progestagen receptors, the state of
the epidermal growth factor receptor 2 (HER2), the
histologic grade and the stage of the disease. We also
compared the immunohistochemical expression of
proCol11A1 to the disease-free interval, and to overall
survival. Results: The immunohistochemical analysis
showed that proCOL11A1 was expressed in 100% of
infiltrating ductal carcinomas, but only focally expressed
in 2.2% (1 case) of sclerosing adenosis, in agreement
with RT-qPCR results. ProCOL11A1 expression did not
prove to have a prognostic value in relation to the
disease-free interval or to overall survival in infiltrating
ductal carcinoma. Conclusion: The anti-proCOL11A1
pAb is a stromal marker for breast cancer and the
expression of proCOL11A1 does not seem to have a
prognostic value in infiltrating ductal carcinoma of the
breast.
Key words: Collagen type XI, Breast carcinoma,
Stromal marker, Immunhistochemistry, Polymerase,
Chain reaction
Introduction
Breast carcinoma ranks first in incidence and
mortality among women, hence the importance of
advancing in early diagnosis and treatment (Parkin et al.,
2001). Several studies have pointed out different
molecular targets localized in the epithelial component
of these malignancies; however, to the best of our
knowledge, there is not any molecular target in the
fibroblasts of the desmoplasia of this type of cancer.
In a previous study on pancreatic cancer, our group
identified the overexpression of the COL11A1 gene
using DNA microarrays and RT-qPCR. Besides, in order
to differentiate chronic pancreatitis from ductal
pancreatic adenocarcinoma, we generated a rabbit
polyclonal antibody anti-proCOL11A1 pAb which stains
fibroblasts of pancreatic cancer desmoplasia with high
specificity and sensitivity, but not chronic pancreatitis
fibroblasts (Barneo et al., 2006). COL11A1 gene up-
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regulation has been reported in some other scenarios,
such as colon adenocarcinoma (Fischer et al., 2001a,b),
non-small cell lung cancer (Chong et al., 2006),
squamous cell carcinoma of head/neck (Sok et al., 2003)
and infiltrating ductal carcinoma (IDC) of the breast
(Feng et al., 2007; Goldstein, 2007). However, to the
best of our knowledge, protein expression has only been
characterized by Halsted et al (Halsted et al., 2008).
They described a low COL11A1 expression in IDC
compared to benign breast tissue, in contrast with our
results.
Type XI Collagen is a type of fibrillar collagen that
plays a key role in the fibrillar network regulation of the
cartilage matrix. It is composed of three polypeptides
alpha 1, alpha 2 and alpha 3, encoded by COL11A1,
COL11A2, and COL11A3 genes, respectively. The alpha
1 chain is synthesized as proCOL11A1, to which our
antibody binds. Anti-proCOL11A1 was designed to
recognize the proCOL11A1 protein fraction less
homologous to proCOL11A2 and proCOL5A1, which
are the procollagens most similar to proCOL11A1
(Fichard et al., 1994). 
Taking into account the reports to date pointing to
COL11A1 gene overexpression in different
malignancies, including breast carcinoma, we decided to
validate the expression of proCOL11A1 by RT-qPCR
and immunohistochemistry in IDC, and to study how it
relates to classical prognostic and predictive factors in
breast cancer, as well as to survival.
Materials and methods
Tissue samples
95 cases of paraffin-embedded core needle biopsies
from the Pathology Department of Hospital
Universitario Central de Asturias (HUCA) were
analyzed: 45 cases of sclerosing adenosis (SA) and 50
cases of IDC. The study complies with the Helsinki
Declaration and was approved by the HUCA ethics
committee.
COL11A1 gene expression analysis by RT-qPCR
Total RNA was isolated from a subset of 14 tissue
biopsies (7 IDC and 7 SA) using TRIzol reagent (Life
Technologies), and cDNA was synthesized with the
reverse transcriptase enzyme SuperScript II RNAse (Life
Technologies). All PCR reactions were run in duplicate
on a 2.0 LightCycler® (Roche Diagnostics) using the
FastStart DNA master SYBR Green I kit (Roche) and
following the manufacturer’s instructions. Primer
sequences were as follows: COL11A1 (target gene):
forward 5’ TGTCGCCAACAAAATTCTCA 3’, reverse
5’ TGTCGGCAGAGAAGAGTTGA 3’; PUM1 pumilio
homolog 1 (reference gene) (Lyng et al., 2008): forward
5’ CAGTCAAAAGGACGTGCAAA 3’, reverse 5’
TACAAAAGGGAAGGGCGATT 3’. The efficiency of
the PCR reactions was calculated using reference curves
with serial dilutions of cDNA, and Ct values were
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obtained using the Fit Points quantification method
(LightCycler® Software 4.05, Roche). COL11A1
expression data were normalized to the reference gene
and corrected for differences in PCR efficiency. Finally,
gene expression data were compared between IDC and
SA samples using the Mann-Whitney U test.
Generation of a rabbit polyclonal antiserum to the
variable region of human procollagen 11A1 (anti-
proCOL11A1pAb)
We have previously described the generation of this
antiserum (Barneo et al., 2006). Briefly, the DNA
sequence coding for the 133 amino acid stretch (E268 to
E400), within the variable region of human
proCOL11A1, was expressed in fusion with GST
(COL11A1-T-GST). The recombinant truncated (T)
fusion protein was purified by affinity chromatography
on glutathione columns and used to immunize New
Zealand white rabbits by intramuscular injection, at 2-
week intervals. The resulting antisera were extensively
depleted of the anti-GST reactivity by chromatography
on GST-agarose columns. This anti-COL11A1-T
purified rabbit IgG recognized COL11A1-T but not
proCOL5A1.
Immunohistochemistry
The tissue obtained from the breast biopsies was
fixed in 10% formaldehyde, paraffin embedded and cut
at 3 µm thick and stained with H&E for histological
examination. Antigen retrieval was done by heating in
PTLink (DakoCytomation, Denmark) in buffer solution
at high pH for 20 minutes. Endogenous peroxidase
activity was blocked with Peroxidase Blocking Reagent
(DakoCytomation, Denmark) for 5 minutes. Samples
were incubated at 37°C with the primary antibodies :
estrogen receptor (Clone 6F11 mAb, dilution 1:400,
Novocastra Laboratories Ltd, United Kingdom),
progesterone receptor (Clone PgR 636 mAb, prediluted,
Dako, Denmark), HER2 (Kit 5206 mAb, dilution 1:100,
Dako, Denmark) and Anti-proCol11A1 pAb (dilution
1:2000 in buffer S2022 (Dako)).
The samples were incubated with the EnVision HRP
Flexsystem (DakoCytomation, Denmark) for 30 minutes
at room temperature and stained with DAB (3-3’-
Diaminobenzidine) (Dako, Denmark) for 10 minutes.
Finally, the samples were counterstained for 10 minutes
with hematoxylin. 
For those HER2 cases which showed uncertain
immunohistochemical positivity (2+), chromogenic in
situ hybridation (CISH) was performed using HER2
CISH kit (pharmDx™ Kit, DakoCytomation, Denmark).
Immunohistochemical assessment
Anti-proCol11A1 pAb
Staining was separately evaluated by two
pathologists (N.F-M/C.G-P), taking into account the two
following parameters
1-Number of positive fields 10X (NPF)
A maximum of four fields of 10X were analyzed,
selecting the largest area and the most intensely stained
field. This decision was based on the focal staining
pattern of anti-proCOL11A1 pAb. Cases which
presented 4 positive fields were assigned the maximum
score of 1, while negative cases were assigned the
minimum score of 0. The score was obtained by dividing
the number of positive fields into the number of assessed
fields.
2-Percentage of stained cells in relation to total
stromal surface (%C/SS)
A field of 20X with the largest area and the most
intense staining was chosen. Cases with less than 10%
positive cells in relation to the stromal surface were
assigned a score of 1, cases with between 10% and 50%
were assigned a score of 2, and cases with more than
50% positive cells were assigned a score of 3 (Fig. 1).
Negative cases were scored with 0.
Estrogen receptor (ER), progesterone receptor (PR) and
epidermal growth factor receptor 2 (HER2):
ER and PR staining was assessed using the Allred
score system (Allred et al., 1998) which considers the
percentage of stained cells and the intensity of stain, on a
scale from 0 to 8. HER2 staining was assessed according
to the recommendations of the College of American
Pathologists guidelines 2007 (Wolff et al., 2007).
Statistical method
Statistical analysis was carried out using the freely
available software package R2.10 (www.r-project.org).
Inter-observer correlation was assessed using the Kappa
index. The c2 (chi-square) test was used for the
comparison of IDC and SA groups, as well as to analyze
how anti-proCOL11A1 pAb expression related to the
other variables. A receiver operating characteristics
(ROC) curve was drawn, with the aim of studying the
sensitivity and specificity of anti-proCOL11A1 pAb as a
marker to discriminate between IDC and SA. The
analysis of survival data was performed using the
Kaplan-Meier survival curve. To compare the two
curves, the logRank test was used. Besides, Cox
proportional hazards model was used to measure the
differences between the two curves. P-values under 0.05
were considered statistically significant.
Results
Sample description
Table 1 contains the description of the sample. 95
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Fig. 1. Immunohistochemical staining with anti-proCOL11A1 pAb. A.
Infiltrating ductal carcinoma (IDC) score 3 (more than 50% cells/SS). B.
IDC score 2, (positive cells between 10-50%/SS). C. IDC score 1
(positive cells under 10%/SS), arrow. x 20
cases were analyzed, 45 of which were SA and 50 were
IDC cases. As regards hormone receptors expression and
HER2 in IDC, 38 cases were positive for hormone
receptors and 5 were positive for HER2. Out of 12 cases
which were negative for ER and PR, 11 were negative
for HER2 (triple-negatives). Out of 5 cases which were
positive for HER2, 3 were confirmed by immunohisto-
chemistry and 2 by CISH. 
COL11A1 gene overexpression
Real-time quantitative RT-qPCR data showed that
COL11A1 is strongly overexpressed in IDC samples
compared to samples of SA, with a significant mean fold
change of 18.7 (p=0.025, two-tailed Mann-Whitney U-
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Fig. 3. Immunohistochemical staining with anti-proCOL11A1 pAb in sclerosing adenosis (SA) and infiltrating ductal carcinoma (IDC). A. Diffuse
positivity for anti-proCOL11A1 pAb in IDC desmoplasia. Negativity of epithelial cells and absence of background staining. B. Negativity of stromal cells
in SA. x 20
Fig. 2. Normalized gene expression levels of COL11A1 in infiltrating
ductal carcinoma (IDC) samples compared to sclerosing adenosis (SA):
(p<0.025), Mann-Whitney test.
Table 1. Patient’s Description.
SA n(%) IDC n(%)
Gender Female 45 (100) 49 (98)
Male 0 1 (2)
Age (years) Average(range) 46 (33-66) 61 (36-93)
Menopause Yes 10 (22,2) 35 (70)
No 35 (77,8) 14 (28)
Histology Grade 1 10 (20)
2 23 (46)
3 17 (34)
Stage 1 16 (32)
2 19 (38)
3 9 (18)
4 6 (12)
NPF Score= 0 44 (97,8) 0
Score>0 1 (2,2) 50 (100)
%C/SS Score=0 44 (97,8) 0
Score>0 1 (2,2) 50 (100)
Her-2 Positive 5 (10)
Negative 45 (90)
Estrogen Receptors Score=0 12 (24)
Score>0 38 (76)
Progesterone Receptors Score=0 19 (38)
Score>0 31 (62)
Survival time(60 months) Dead 0 12 (24)
Alive 45 (100) 38 (76)
n, number of cases; SA, sclerosing adenosis; IDC, infiltrating ductal
carcinoma; NPF, number of positive fields; %C/SS, percentage of
stained cells in relation to total stromal surface.
test) (Fig. 2).
Immunohistochemical evaluation of anti-proCol11A1 pAb
All cancer samples tested with anti-proCOL11A1
pAb showed intracytoplasmatic labeling of tumor-
surrounding desmoplastic stromal fibroblasts (Fig. 3A).
In some cases the staining was focal with uneven
distribution. Extracellular staining was never observed.
In contrast, the expression of proCOL11A1 in SA was
either absent (Fig. 3B) or low and restricted to a few
fibroblasts.
The Kappa index showed an inter-observer
correlation of 0.754 for NPF and of 0.805 for %C/SS.
The difference in proCOL11A1 expression when
comparing IDC and SA groups was statistically
significant (p<0.001). Only 1 SA case (2.2%) was
positive, compared to 100% of IDC cases that were
positive (Table 2). Sensitivity and specificity of anti-
proCOL11A1 pAb to discriminate between IDC and SA
were 100% and 97.8%, respectively, with a cut-off point
of 0 (Fig. 4).
The relationship of proCOL11A1 to other predictive and
prognostic variables, the disease-free interval, and
overall survival
The expression of proCol11A1 did not have a
statistically significant relationship with the histologic
grade of IDC (p=0.450 for NPF; p=0.621 for %C/SS),
nor with the stage of the disease (p=0.292 for NPF;
p=0.480 for %C/SS), although cases with a higher score
in NPF and %C/SS had a histologic grade of 2 or 3 (40
cases) compared to cases with a lower score, which had
a histologic grade of 1 (10 cases).
Likewise, the earlier stages of the disease showed
higher scores than the later stages. The relationship to
HER2 expression was not statistically significant
(p=0.497 for NPF; p=0.239 for %C/SS). The 5 positive
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Fig. 5. The curve shows higher mortality for cases with score 1 for NPF
(10 deceased cases with score 1 and only 2 deceased cases with score
<1). This relationship was not statistically significant (p=0.195, 95%
CI[0.597-12.457]). Kaplan Meier.
Fig. 4. ROC curves of infiltrating ductal carcinoma (IDC) vs. sclerosing
adenosis (SA). The number of positive fields (NPF) ROC curve and the
percentage of stained cells in relation to total stromal surface (%C/SS)
ROC curve show a sensitivity of 100% and a specificity of 97.8% (cut
off=0).
Table 2. Comparison of anti-proCol11A1 pAb between sclerosing
adenosis and infiltrating ductal carcinoma. 
SA IDC
NPF P<0,001 0 44 (97,8%) 0
0,25 0 3 (6%)
0,50 0 4 (8%)
0,75 1 (2,2%) 9 (18%)
1 0 34 (68%)
%C/SS P<0,001 0 44 (97,8%) 0
1 0 6 (12%)
2 1 (2,2%) 11 (22%)
3 0 33 (66%)
SA, sclerosing adenosis; IDC, infiltrating ductal carcinoma; NPF,
number of positive fields; %C/SS, percentage of stained cells in relation
to total stromal surface.
cases for HER2 showed a score of 1 for NPF and a score
of 3 for %C/SS. Cases which showed more expression
for hormone receptors, showed lower proCOL11A1
expression. As regards ER, this relationship was not
statistically significant (p=0.416 for NPF; p=0.351 for
%C/SS); however, for PR, a statistically significant
relationship with NPF (p=0.008) was observed, and a
non-significant one with %C/SS (p=0.430). On the other
hand, the relationship between the disease-free interval
and the expression of proCOL11A1 was not statistically
significant (p=0.161); nevertheless, the 5 relapsed cases
showed score 1 for NPF. Lastly, although the
relationship between survival and proCOL11A1
expression was not significant, out of the 12 deceased
cases, 10 presented a score 1 for NPF (p=0.176) (Fig. 5).
It is worth noting that the hazard ratio (HR) observed
was 2.73 [95% CI of (0.597-12.457)], somewhat lower
when adjusted for age and stage: 2.38 (0.46-12.22).
Discussion
In a previous study on pancreatic cancer our group
demonstrated the overexpression of COL11A1 gene
using DNA microarrays and RT-qPCR (Barneo et al.,
2006). Also, in order to differentiate chronic pancreatitis
from ductal pancreatic adenocarcinoma, we generated an
antibody anti-proCOL11A1pAb which we proposed as a
potential desmoplastic stromal marker (García-Ocaña et
al., 2012). Taking those results into account, we decided
to study the expression of -proCOL11A1 in IDC
desmoplasia.
A recent computational analysis of gene expression
from multiple cancers, including breast cancer, reveals
that overexpression of COL11A1 and other genes is a
high specificity biomarker of cancer invasion and
predicts the response to neoadjuvant therapy. In this
analysis, the authors describe a sub-type of COL11A1-
producing fibroblasts which they call metastasis-
associated fibroblasts (MAFs), and which belong to the
cancer-associated fibroblasts class (CAFs) (Kim et al.,
2010). The presence of the core genes of the MAF
signature in breast cancer would be a good indicator of
resistance to neoadjuvant chemotherapy. 
As the staining with anti-proCOL11A1pAb is
negative in fibroblasts of normal breast and almost
absent in a benign inflammatory process, this is
suggestive that this staining could be a specific marker
of CAFs. Work is in progress to demonstrate by
immunohistochemical methods whether fibroblasts with
anti-proCOL11A1 pAb staining also have the MAF
signature. In any case, the origin of the fibroblasts
expressing proCOL11A1 falls beyond the aims of this
study. Nevertheless, we can affirm that this fibroblast
subpopulation is present in 100% of IDC, but only in
very few cases of SA. 
From the genetic point of view, Vargas et al
demonstrated that the COL11A1 gene is up regulated in
epithelial and stromal cells of IDC in comparison with in
situ carcinoma (Vargas et al., 2012). We proved an up
regulation of COL11A1 in IDC in comparison with SA;
however, since that was not an objective of our study, we
did not analyze whether those expressions came from
epithelial or from mesenchymal cells.
To the best of our knowledge, only Halsted et al.
used anticollagen11 antibodies to differentiate protein
expression in IDC and normal breast tissue. They used 5
different types of antibodies against different fractions of
COL11A1. Their results were in contradiction to ours,
because they saw a low expression of COL11A1 in
breast cancer in comparison with normal tissue (Halsted
et al., 2008). In this regard, we took into account the
similarities between COL11A1 and other types of
collagen, designing a very specific antibody against the
less homologous fraction of proCOL11A1 in comparison
with COL5A1 and COL11A2, avoiding a cross reaction
between those similar collagens. Furthermore, the
evaluation parameters we used results in a low
interobserver variability, which is patent in the high
correlation between the assessments of the two
pathologists. Finally the results of genetic analysis by
RT-qPCR support our immunohistochemical findings. 
On the other hand, the relationship observed
between proCOL11A1 expression and ER, and with PR,
has been similar to that reported by Halsted et al. It is an
inverse relation, where proCOL11A1 is less expressed in
cases which show a more intense and widespread
staining with hormone receptors (Halsted et al., 2008).
These are interesting results although we cannot assert
that proCOL11A1 is a prognostic marker in IDC, since
this relationship was not statistically significant in our
study. The fact that the relationship between PR and
NPF is significant and that it is not in the case of %C/SS,
might suggest that this relationship may be stronger
when considering the area of stain in the sample and not
the focal percentage of stained cells.
On the other hand, the expression of proCOL11A1
does not have a prognostic value in our study, since it
has no relation with the disease-free interval nor with
overall survival. Nonetheless, some observations should
be taken into account for future studies, such as the fact
that this marker seems to have more expression in
HER2-positive tumors, in those with a higher histologic
grade and in the earliest stages of disease. It is also
worth noting that the cases which presented relapses of
the disease, and most of the deceased cases, were among
the ones where proCOL11A1 was most expressed.
Maybe if the sample was increased, a statistically
significant relation might exist between the disease-free
interval/survival and this marker's expression. 
Although it wasn’t an objective of our study, the data
exposed demonstrated that antiproCol11A1 is useful to
differentiate between SA and IDC. The differential
diagnosis between both entities is usually easy, although
the anti-proCOL11A1 pAb antibody could be used in
difficult cases, taking into account the lack of other
specific markers of stromal desmoplastic fibroblasts. 
We conclude that proCOL11A1 is overexpressed in
IDC of breast and anti-proCol11A1 pAb is a stromal
92
COL11A1 in breast cancer
marker of IDC desmoplasia. We have not found a
prognostic value for its immunohistochemical
expression, nor a correlation with other prognostic or
predictive factors. 
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